KRO
Kronos Worldwide, Inc.
Chemicals - Specialty
Market Cap$811M
5Y Perf.-27.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
KRO vs CC
Revenue, margins, valuation, and 5-year total return — side by side.
CC
The Chemours Company
Chemicals - Specialty
Market Cap$3.36B
5Y Perf.+70.9%
KRO vs CC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | KRO | CC |
|---|---|---|
| Industry | Chemicals - Specialty | Chemicals - Specialty |
| Market Cap | $811M | $3.36B |
| Revenue (TTM) | $1.88B | $5.82B |
| Net Income (TTM) | $-134M | $-411M |
| Gross Margin | 10.1% | 15.1% |
| Operating Margin | -3.1% | -0.8% |
| Forward P/E | — | 15.5x |
| Total Debt | $577M | $4.58B |
| Cash & Equiv. | $37M | $672M |
KRO vs CC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KRO
CC
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Kronos Worldwide, I… (KRO) | 100 | 72.2 | -27.8% |
| The Chemours Company (CC) | 100 | 170.9 | +70.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KRO vs CC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CC leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Kronos Worldwide, Inc. is the stronger pick specifically for capital preservation and lower volatility and dividend income and shareholder returns. As sector peers, any of these can serve as alternatives in the same allocation.
KRO
Kronos Worldwide, Inc.
The Income Pick
KRO is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 0 yrs, beta 1.57, yield 2.8%
- Rev growth -1.5%, EPS growth -228.0%, 3Y rev CAGR -1.2%
- Lower volatility, beta 1.57, Low D/E 76.9%, current ratio 2.70x
Best for: income & stability and growth exposure
CC
The Chemours Company
The Long-Run Compounder
CC carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 219.7% 10Y total return vs KRO's 129.0%
- 0.4% revenue growth vs KRO's -1.5%
- -7.1% margin vs KRO's -7.1%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CC | 0.4% revenue growth vs KRO's -1.5% |
| Quality / Margins | CC | -7.1% margin vs KRO's -7.1% |
| Stability / Safety | KRO | Beta 1.57 vs CC's 1.92, lower leverage |
| Dividends | KRO | 2.8% yield, vs CC's 2.3% |
| Momentum (1Y) | CC | +108.8% vs KRO's -1.2% |
| Efficiency (ROA) | CC | -5.5% ROA vs KRO's -9.4%, ROIC -0.1% vs -1.9% |
KRO vs CC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2014
FY 2025
KRO vs CC — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLKROLAGGINGCC
CCThe Chemours Company
2leads
KROKronos Worldwide, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs CCMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CC4/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
KRO5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
CC4/6
Risk & VolatilityBeta, volatility, and downside exposure
KRO2/2
Analyst OutlookRatings, price targets, and dividends
KRO1/1
Income & Cash Flow (Last 12 Months)
CC leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CC is the larger business by revenue, generating $5.8B annually — 3.1x KRO's $1.9B. Profitability is closely matched — net margins range from -7.1% (CC) to -7.1% (KRO). On growth, KRO holds the edge at +4.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | KROKronos Worldwide,… | CCThe Chemours Comp… |
|---|---|---|
| RevenueTrailing 12 months | $1.9B | $5.8B |
| EBITDAEarnings before interest/tax | -$9M | -$132M |
| Net IncomeAfter-tax profit | -$134M | -$411M |
| Free Cash FlowCash after capex | $35M | $198M |
| Gross MarginGross profit ÷ Revenue | +10.1% | +15.1% |
| Operating MarginEBIT ÷ Revenue | -3.1% | -0.8% |
| Net MarginNet income ÷ Revenue | -7.1% | -7.1% |
| FCF MarginFCF ÷ Revenue | +1.9% | +3.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +4.1% | +1.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -126.1% | -6.1% |
CC leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
Evenly matched — KRO and CC each lead in 2 of 4 comparable metrics.
Valuation Metrics
On an enterprise value basis, CC's 21.7x EV/EBITDA is more attractive than KRO's 40.7x.
| Metric | KROKronos Worldwide,… | CCThe Chemours Comp… |
|---|---|---|
| Market CapShares × price | $811M | $3.4B |
| Enterprise ValueMkt cap + debt − cash | $1.4B | $7.3B |
| Trailing P/EPrice ÷ TTM EPS | -7.34x | -8.75x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 15.55x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 40.71x | 21.72x |
| Price / SalesMarket cap ÷ Revenue | 0.44x | 0.58x |
| Price / BookPrice ÷ Book value/share | 1.08x | 13.44x |
| Price / FCFMarket cap ÷ FCF | — | 65.93x |
Evenly matched — KRO and CC each lead in 2 of 4 comparable metrics.
Profitability & Efficiency
KRO leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
KRO delivers a -17.0% return on equity — every $100 of shareholder capital generates $-17 in annual profit, vs $-163 for CC. KRO carries lower financial leverage with a 0.77x debt-to-equity ratio, signaling a more conservative balance sheet compared to CC's 18.27x. On the Piotroski fundamental quality scale (0–9), KRO scores 5/9 vs CC's 4/9, reflecting solid financial health.
| Metric | KROKronos Worldwide,… | CCThe Chemours Comp… |
|---|---|---|
| ROE (TTM)Return on equity | -17.0% | -163.4% |
| ROA (TTM)Return on assets | -9.4% | -5.5% |
| ROICReturn on invested capital | -1.9% | -0.1% |
| ROCEReturn on capital employed | -2.2% | -0.1% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.77x | 18.27x |
| Net DebtTotal debt minus cash | $540M | $3.9B |
| Cash & Equiv.Liquid assets | $37M | $672M |
| Total DebtShort + long-term debt | $577M | $4.6B |
| Interest CoverageEBIT ÷ Interest expense | -2.32x | 1.15x |
KRO leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
CC leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CC five years ago would be worth $7,726 today (with dividends reinvested), compared to $5,607 for KRO. Over the past 12 months, CC leads with a +108.8% total return vs KRO's -1.2%. The 3-year compound annual growth rate (CAGR) favors KRO at -0.2% vs CC's -5.5% — a key indicator of consistent wealth creation.
| Metric | KROKronos Worldwide,… | CCThe Chemours Comp… |
|---|---|---|
| YTD ReturnYear-to-date | +58.5% | +83.6% |
| 1-Year ReturnPast 12 months | -1.2% | +108.8% |
| 3-Year ReturnCumulative with dividends | -0.7% | -15.7% |
| 5-Year ReturnCumulative with dividends | -43.9% | -22.7% |
| 10-Year ReturnCumulative with dividends | +129.0% | +219.7% |
| CAGR (3Y)Annualised 3-year return | -0.2% | -5.5% |
CC leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
KRO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
KRO is the less volatile stock with a 1.57 beta — it tends to amplify market swings less than CC's 1.92 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KRO currently trades 89.2% from its 52-week high vs CC's 78.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KROKronos Worldwide,… | CCThe Chemours Comp… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.57x | 1.92x |
| 52-Week HighHighest price in past year | $7.90 | $28.67 |
| 52-Week LowLowest price in past year | $4.08 | $9.13 |
| % of 52W HighCurrent price vs 52-week peak | +89.2% | +78.1% |
| RSI (14)Momentum oscillator 0–100 | 63.4 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 350K | 3.1M |
KRO leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
KRO leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates KRO as "Hold" and CC as "Hold". Consensus price targets imply -1.2% upside for CC (target: $22) vs -29.1% for KRO (target: $5). For income investors, KRO offers the higher dividend yield at 2.84% vs CC's 2.31%.
| Metric | KROKronos Worldwide,… | CCThe Chemours Comp… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold |
| Price TargetConsensus 12-month target | $5.00 | $22.14 |
| # AnalystsCovering analysts | 7 | 20 |
| Dividend YieldAnnual dividend ÷ price | +2.8% | +2.3% |
| Dividend StreakConsecutive years of raises | 0 | 0 |
| Dividend / ShareAnnual DPS | $0.20 | $0.52 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
KRO leads this category, winning 1 of 1 comparable metric.
Key Takeaway
KRO leads in 3 of 6 categories (Profitability & Efficiency, Risk & Volatility). CC leads in 2 (Income & Cash Flow, Total Returns). 1 tied.
Best OverallKronos Worldwide, Inc. (KRO)Leads 3 of 6 categories
Loading custom metrics...
KRO vs CC: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is KRO or CC a better buy right now?
For growth investors, The Chemours Company (CC) is the stronger pick with 0.
4% revenue growth year-over-year, versus -1. 5% for Kronos Worldwide, Inc. (KRO). Analysts rate Kronos Worldwide, Inc. (KRO) a "Hold" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — KRO or CC?
Over the past 5 years, The Chemours Company (CC) delivered a total return of -22.
7%, compared to -43. 9% for Kronos Worldwide, Inc. (KRO). Over 10 years, the gap is even starker: CC returned +219. 7% versus KRO's +129. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — KRO or CC?
By beta (market sensitivity over 5 years), Kronos Worldwide, Inc.
(KRO) is the lower-risk stock at 1. 57β versus The Chemours Company's 1. 92β — meaning CC is approximately 22% more volatile than KRO relative to the S&P 500. On balance sheet safety, Kronos Worldwide, Inc. (KRO) carries a lower debt/equity ratio of 77% versus 18% for The Chemours Company — giving it more financial flexibility in a downturn.
04Which is growing faster — KRO or CC?
By revenue growth (latest reported year), The Chemours Company (CC) is pulling ahead at 0.
4% versus -1. 5% for Kronos Worldwide, Inc. (KRO). On earnings-per-share growth, the picture is similar: Kronos Worldwide, Inc. grew EPS -228. 0% year-over-year, compared to -549. 1% for The Chemours Company. Over a 3-year CAGR, KRO leads at -1. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — KRO or CC?
Kronos Worldwide, Inc.
(KRO) is the more profitable company, earning -6. 0% net margin versus -6. 6% for The Chemours Company — meaning it keeps -6. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CC leads at -0. 1% versus -1. 7% for KRO. At the gross margin level — before operating expenses — CC leads at 15. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is KRO or CC more undervalued right now?
Analyst consensus price targets imply the most upside for CC: -1.
2% to $22. 14.
07Which pays a better dividend — KRO or CC?
All stocks in this comparison pay dividends.
Kronos Worldwide, Inc. (KRO) offers the highest yield at 2. 8%, versus 2. 3% for The Chemours Company (CC).
08Is KRO or CC better for a retirement portfolio?
For long-horizon retirement investors, Kronos Worldwide, Inc.
(KRO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (2. 8% yield, +129. 0% 10Y return). The Chemours Company (CC) carries a higher beta of 1. 92 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KRO: +129. 0%, CC: +219. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between KRO and CC?
Both stocks operate in the null sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(KRO: 4.1% · CC: 1.0%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.